DERIVADOS DE AMINO TRIAZOLO QUINAZOLINA 9-SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA, COMPOSICIONES FARMACEUTICAS Y SU USO

• Main Authors: ALI, Amjad, PLUMMER, Christopher W, HOOVER, Andrew J, CUMMING, Jared, LIU, Kun, LARSEN, Matthew A, DEMONG, Duane, PAN, Jianping, SWAMINATHAN, Uma, ZHANG, Yonglian, GRAHAM, Thomas, H, SATHER, Aaron, WANG, Huijun, HENNESSY, Elisabeth, LIU, Ping, MANSOOR, Umar Faruk, DENG, Qiaolin
• Format: Patent
• Language: Spanish
• Published: 07.09.2021
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

La presente invencion se refiere a un compuesto de formula estructural (I), o una sal farmaceuticamente aceptable del mismo, en donde: R1 es F, Cl, alquilo C1-C6 y O(alquilo C1-C6); R2 es H, F, Cl, alquilo C1-C6 y O(alquilo C1-C6); el anillo A es i), ii), iii), entre otros; R3 es pirazolilo, triazolilo y piridinilo sustituidos con grupos R3A, donde R3A es alquilo C1-C6, O(alquilo C1-C6), entre otros; RA1 es H y alquilo C1-C4; RA2 y RA3 son H, F y alquilo C1-C4. Son compuestos preferidos los compuestos a), b), c), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son derivados de amino triazolo quinazolina 9-sustituidos y antagonistas de los receptores A2a y/o A2b de adenosina, siendo utiles en el tratamiento del cancer. In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I):and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.